TSCAN THERAPEUTICS, INC. Research and Development Expense
TSCAN THERAPEUTICS, INC. (TCRX) reported Research and Development Expense of $23.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- TSCAN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $23.40M, a 28.29% decline year-over-year.
- TSCAN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $21.90M, a 26.47% decline year-over-year.
- TSCAN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $20.04M, a 31.73% decline year-over-year.
- TSCAN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $31.69M, a 20.66% increase year-over-year.
- TSCAN THERAPEUTICS, INC. research and development expense for fiscal 2025 was $114.15M, a 6.33% increase from fiscal 2024.
- TSCAN THERAPEUTICS, INC. research and development expense for fiscal 2024 was $107.35M, a 21.78% increase from fiscal 2023.
- TSCAN THERAPEUTICS, INC. research and development expense for fiscal 2023 was $88.15M, a 47.37% increase from fiscal 2022.
- TSCAN THERAPEUTICS, INC. research and development expense for fiscal 2022 was $59.82M, a 33.07% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.40M 10-Q · filed 2026-08-12 | $45.31M 10-Q · filed 2026-08-12 | $65.34M derived: sum of 3 quarters · filed 2026-08-12 | $97.03M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $21.90M 10-Q · filed 2026-05-06 | $41.94M derived: sum of 2 quarters · filed 2026-05-06 | $73.63M derived: sum of 3 quarters · filed 2026-05-06 | $106.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $51.73M derived: sum of 2 quarters · filed 2026-03-04 | $84.36M derived: sum of 3 quarters · filed 2026-08-12 | $114.15M 10-K · filed 2026-03-04 |
| 2025-09-30 | $31.69M 10-Q · filed 2025-11-12 | $64.32M derived: sum of 2 quarters · filed 2026-08-12 | $94.11M 10-Q · filed 2025-11-12 | $123.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $32.63M 10-Q · filed 2026-08-12 | $62.42M 10-Q · filed 2026-08-12 | $91.78M derived: sum of 3 quarters · filed 2026-08-12 | $118.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $29.79M 10-Q · filed 2026-05-06 | $59.14M derived: sum of 2 quarters · filed 2026-05-06 | $85.40M derived: sum of 3 quarters · filed 2026-05-06 | $112.28M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $29.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $55.62M derived: sum of 2 quarters · filed 2026-03-04 | $82.49M derived: sum of 3 quarters · filed 2026-03-04 | $107.35M 10-K · filed 2026-03-04 |
| 2024-09-30 | $26.26M 10-Q · filed 2025-11-12 | $53.14M derived: sum of 2 quarters · filed 2025-11-12 | $78.00M 10-Q · filed 2025-11-12 | $100.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $26.88M 10-Q · filed 2025-08-12 | $51.73M 10-Q · filed 2025-08-12 | $74.14M derived: sum of 3 quarters · filed 2025-08-12 | $96.88M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $24.86M 10-Q · filed 2025-05-06 | $47.26M derived: sum of 2 quarters · filed 2025-05-06 | $70.00M derived: sum of 3 quarters · filed 2025-05-06 | $91.23M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $22.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $45.15M derived: sum of 2 quarters · filed 2025-03-05 | $66.37M derived: sum of 3 quarters · filed 2025-03-05 | $88.15M 10-K · filed 2025-03-05 |
| 2023-09-30 | $22.74M 10-Q · filed 2024-11-12 | $43.97M derived: sum of 2 quarters · filed 2024-11-12 | $65.75M 10-Q · filed 2024-11-12 | $81.35M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $21.23M 10-Q · filed 2024-08-12 | $43.01M 10-Q · filed 2024-08-12 | $58.61M derived: sum of 3 quarters · filed 2024-08-12 | $73.64M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $21.78M 10-Q · filed 2024-05-13 | $37.38M derived: sum of 2 quarters · filed 2024-05-13 | $52.41M derived: sum of 3 quarters · filed 2024-05-13 | $66.91M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $30.64M derived: sum of 2 quarters · filed 2024-03-06 | $45.13M derived: sum of 3 quarters · filed 2024-03-06 | $59.82M 10-K · filed 2024-03-06 |
| 2022-09-30 | $15.03M 10-Q · filed 2023-11-09 | $29.52M derived: sum of 2 quarters · filed 2023-11-09 | $44.22M 10-Q · filed 2023-11-09 | $56.82M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $14.49M 10-Q · filed 2023-08-10 | $29.18M 10-Q · filed 2023-08-10 | $41.79M derived: sum of 3 quarters · filed 2023-08-10 | $56.00M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $14.69M 10-Q · filed 2023-05-10 | $27.30M derived: sum of 2 quarters · filed 2023-05-10 | $41.50M derived: sum of 3 quarters · filed 2023-05-10 | $52.30M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $26.81M derived: sum of 2 quarters · filed 2023-03-08 | $37.62M derived: sum of 3 quarters · filed 2023-03-08 | $44.95M 10-K · filed 2023-03-08 |
| 2021-09-30 | $14.21M 10-Q · filed 2022-11-09 | $25.01M derived: sum of 2 quarters · filed 2022-11-09 | $32.35M 10-Q · filed 2022-11-09 | $38.31M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $10.80M 10-Q · filed 2022-08-10 | $18.14M 10-Q · filed 2022-08-10 | $24.10M derived: sum of 3 quarters · filed 2022-08-10 | $29.92M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $7.34M 10-Q · filed 2022-05-12 | $13.30M derived: sum of 2 quarters · filed 2022-05-12 | $19.12M derived: sum of 3 quarters · filed 2022-05-12 | $23.62M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $11.78M derived: sum of 2 quarters · filed 2022-03-09 | $16.28M derived: sum of 3 quarters · filed 2022-03-09 | $20.58M 10-K · filed 2022-03-09 |
| 2020-09-30 | $5.81M 10-Q · filed 2021-11-10 | $10.31M derived: sum of 2 quarters · filed 2021-11-10 | $14.61M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.50M 10-Q · filed 2021-08-19 | $8.80M 10-Q · filed 2021-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B |